IPA - ImmunoPrecise Antibodies Ltd.
Chart Events
Inside Bar (Bullish)
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.7800 |
| Open | 2.7500 |
| Bid | 3.0700 x 900 |
| Ask | 3.1800 x 900 |
| Day's Range | 2.7500 - 3.1799 |
| 52 Week Range | 2.3500 - 6.5000 |
| Volume | |
| Avg. Volume | 90,962 |
| Market Cap | 78.22M |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings Date | Jul 27, 2023 - Jul 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.99 |
Fair Value
Related Research
Business WireIPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
VICTORIA, British Columbia, May 30, 2023--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company"), an AI-driven biotherapeutic research and technology company, today announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma (IID) by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3D structural data
Business WireIPA to Present at Jefferies Healthcare Conference 2023
VICTORIA, British Columbia, May 17, 2023--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company") an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time.
Business WireImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
VICTORIA, British Columbia, March 30, 2023--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("ImmunoPrecise" or "IPA" or the "Company") an AI-driven biotherapeutic research and technology company today announced a research collaboration and exclusive option license agreement with Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., "Astellas"). Under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary LENSai
Business WireEuropean Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
VICTORIA, British Colombia, March 27, 2023--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) ("Immunoprecise" or "IPA" or the "Company"), the parent company of BioKey and affiliate of BioStrand, announced today that the EPO has issued a "Decision to Grant" for BioKey’s patent application covering the company’s HYFT® Technology used to organize and analyze biological sequence information. The HYFT Technology and methodology provide a novel way to efficiently tap into sequence information, allowing the
Business WireImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
VICTORIA, British Colombia, March 23, 2023--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) ("Immunoprecise" or "IPA" or the "Company"), an AI-driven biotherapeutic research and technology company, is pleased to announce that its wholly owned subsidiary, Talem Therapeutics, will present a scientific poster with their latest data on the development of bispecific T-cell engagers targeting TrkB at the annual AACR meeting in Orlando, Florida, which is held from April 14 to 19, 2023. With this advanced d
Business WireIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023
VICTORIA, British Columbia, March 16, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for third quarter fiscal year 2023, which ended January 31, 2023.
Business WireImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
VICTORIA, British Columbia & SANTIAGO DE COMPOSTELA, Spain, March 15, 2023--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) ("Immunoprecise" or "IPA" or the "Company"), an AI-driven biotherapeutic research and technology company, today announced that Talem Therapeutics LLC, an independently operating subsidiary of IPA, and Libera Bio S.L., have signed a collaboration agreement to jointly address intracellular targets. It is estimated that 75% of disease-causing targets are located inside cells1. Som
Business WireIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023
VICTORIA, British Columbia, March 07, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for third quarter fiscal year 2023, on Thursday, March 16, 2023, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
Business WireIPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023
VICTORIA, British Columbia, December 15, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for second quarter fiscal year 2023, which ended October 31, 2022.
Business WireIPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments
VICTORIA, British Columbia, December 08, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that its subsidiary, BioStrand BV, has completed the full integration of 20 million Structural HYFTs with Deepmind’s AlphaFold and META’s ESM-2 Fold platforms.
Business WireIPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022
VICTORIA, British Columbia, December 05, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2023, on Thursday, December 15, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
Business WireIPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA, November 30, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology c
Business WireImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
VICTORIA, British Columbia, November 22, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a voluntary delisting of its common shares from the TSX Venture Exchange ("TSXV"). Accordingly, it is anticipated that, effective as at the close of trading on Friday, November 25, 2022, IPA’s common shares will no longer be listed and posted for trading on the TSXV.
Business WireIPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
VICTORIA, British Columbia, October 12, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), today announced that its subsidiary, Talem Therapeutics LLC ("Talem"), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated. The agreement builds upon Talem’s extensive antibody development expertise and its access to LENSai™ in silico software technology to further the development and commerciali
Business WireNIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
VICTORIA, British Columbia, September 14, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), announced today that its subsidiary, Talem Therapeutics LLC ("Talem"), has shared positive results of a new study conducted by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), that has shown the continued resilience of PolyTope® TATX-03 in broadly neutralizing SARS-Co-V-2 variants, including two O
Business WireIPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
VICTORIA, British Columbia, September 14, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2023, which ended July 31, 2022.
Business WireIPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
VICTORIA, British Columbia, September 08, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2023, on Wednesday, September 14, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
Business WireLive Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
VICTORIA, British Columbia, August 29, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), a biotherapeutic research and technology company, today announced the continuing success of PolyTope® TATX-03 antibody combination therapy to neutralize variants of concern of the COVID-19 causative virus, including the latest Omicron BA.5 subvariant, validated by an independent research organization in an authentic virus assay.
Business WireImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
VICTORIA, British Columbia, July 29, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended April 30, 2022.
Business WireIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
VICTORIA, British Columbia, July 26, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its financial results and recent business highlights for fourth quarter and full fiscal year 2022, on Friday, July 29, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.
Business WireHistopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
VICTORIA, British Columbia, July 12, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, reports the critical third-party findings of two IND-enabling pre-clinical safety studies, de-risking the clinical development of the Company’s PolyTope® TATX-03 antibody cocktail and its potential to prevent and treat COVID-19. A summary of the positive findings indicates that, through ex vivo screenings, n
Simply Wall St.Despite currently being unprofitable, ImmunoPrecise Antibodies (CVE:IPA) has delivered a 44% return to shareholders over 3 years
ImmunoPrecise Antibodies Ltd. ( CVE:IPA ) shareholders have seen the share price descend 18% over the month. But that...